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Abstract 
We describe an extremely severe case of therapy refractory NMDA receptor encephalitis 
(NMDAe) in a 26-year-old woman. After rituximab, bilateral oophorectomy, repeated cycles 
of high dose methylprednisolone and plasma exchange, she received repeated 
cyclophosphamide, tocilizumab (interleukin-6 inhibitor) and finally bortezomib (plasma cell 
depleting drug) leading to remission after 204 days in intensive care. Two years after disease 
onset her cognitive functions are still affected, but slowly improving and the cerebral atrophy 
has been partly reversed. The cerebrospinal fluid biomarker profile suggests an early 
synaptic/dendritic degeneration, with subsequent neuroaxonal loss motivating aggressive 
treatment early on. 
 
Highlights 
• Targeting B- and plasma cells can be effective in refractory anti-NMDAR encephalitis  
• Neuronal cell loss is relatively limited in anti-NMDAR encephalitis  
• Brain atrophy can be reversible in anti-NMDAR encephalitis 
• This may explain the good long-term prognosis in those surviving the acute phase 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1. Introduction 
NMDA receptor encephalitis (NMDAe) is an antibody-mediated autoimmune disorder, first 
described as a discrete entity by Dalmau and colleagues after observing four female patients 
with teratoma and neuropsychiatric symptoms (Vitaliani et al., 2005). Subsequently, the target 
antigen was identified as the NR1 subunit of the NMDA-receptor, which is abundantly 
expressed in the frontal and hippocampal regions of the brain (Dalmau et., al 2005). NMDAe 
occurs both as a paraneoplastic and an autoimmune or parainfectious condition, the latter 
sometimes triggered by herpes simplex encephalitis. NMDAe is likely to be the most common 
form of the paraneoplastic encephalitides and the most common autoimmune encephalitis 
second to acute disseminated encephalomyelitis (Granerod et al., 2010). NMDAe has a wide 
clinical spectrum; from mild to very severe disease, where mortality rates are as high as 20% 
(Titulaer et al., 2013), but specific treatment algorithms remain to be established. 
Furthermore, it is currently not known if the character or degree of neuronal tissue injury 
differs between NMDAe and other types of inflammatory encephalitides. A large proportion 
of patients do not have focal injuries visible on magnetic resonance imaging (MRI), while 
others display hyperintense lesions predominately in the hippocampi, but also in other areas. 
In severe cases global brain atrophy, mainly in fronto-temporal regions, may be prominent. In 
classical forms of paraneoplastic encephalitides, specific nerve cell populations are targeted, 
leading to loss of neurons and permanent deficits. In contrast, a remarkable finding in a long-
term follow-up of two patients with severe NMDAe was that a pronounced fronto-temporal 
atrophy during the acute phase of the disease was reversible (Lizuka et al., 2013). The 
biological basis for this phenomenon is unknown and reports on biomarker profiles in 
NMDAe are limited (Constantinescu et al., 2016).  
 
2. Case report 
A 26-year-old woman of Southeast Asian descent, with no relevant medical family history of 
autoimmune or psychiatric disease, presented with a rapidly progressing personality disorder, 
with aggressive behavior, emotional liability, suicidal ideation, visual and auditory 
hallucinations, insomnia and memory impairment, followed by repeated generalized seizures. 
Despite initial treatment with antiepileptic drugs (AEDs) she developed status epilepticus and 
was transferred to neurointensive care. On admission, the CSF analysis revealed a 
moderate lymphocytic pleocytosis (60 cells/mm3), which had risen to 190 cells/mm3 one week 
later. Extensive virus and bacterial screens were negative. Suspecting an autoimmune 
disorder, the patient began treatment with high dose methylprednisolone six days after 
admission, rituximab and initiation of plasma exchange 13 days after admission, a total of 4 
cycles (18 sessions) over a four-month period. Anti-NMDAR antibodies were subsequently 
confirmed in serum and CSF (see Fig 1, for antibody titer progression). Antibody 
titers remained high despite treatment and undetectable B cells in peripheral blood. No 
teratoma or tumor was detected with whole body PET or CT. MRI of the pelvis revealed 
polycystic ovaries, which made it impossible to exclude the presence of a small teratoma. The 
patient underwent a bilateral oophorectomy (day 62), without signs of teratoma on 
histopathology. As a next step cyclophosphamide was initiated with a total of 7 cycles (1000 
mg per cycle) over four months. The patient remained continuously sedated on propofol, 
midazolam and morphine with the addition of two to three AEDs but intermittent wake up 
attempts resulted in increased dyskinesia and epileptiform activity. EEG monitoring revealed 
a predominant delta and theta frequencies with instances of highly characteristic extreme 
delta-brush activity (Schmitt et al., 2012). The absence of clinical improvement despite four 
months of intensive care motivated additional immunological approaches. This was also 
motivated by the monitoring of neurofilament-light (NFL), a neuroaxonal injury marker, 
which remained elevated at moderate to high levels (Fig. 1). As a first step tocilizumab, a 
blocker of interleukin-6 signaling with suggested effects in refractory neuromyelitis optica 
(Chihara et al., 2011; Araki et al., 2014), was given at a dose of 8 mg/kg at day 119. As the 
next step 25 mg of rituximab was administered intrathecally at day 133 since CSF flow 
cytometry revealed a normal proportion (7%) of B-cells despite peripheral blood depletion. 
Intrathecal B-cell counts fell to 1.5% (3 cells) at follow-up, one month later. Clinically, 
however, the patient showed no signs of improvement. Follow-up MRI scans taken five 
months after admission showed a marked progression of atrophy most prominent in fronto-
temporal regions (Fig. 2). Finally, it was deemed necessary to initiate treatment with 
bortezomib, a protease inhibitor that results in the depletion of plasma cells. Bortezomib was 
given as at a dose of 1.3mg/m2 mg in 4 repeated weekly injections from day 147. Over the 
following four weeks, the patient started to display a remarkable improvement considering the 
time spent in critical care. Seven months after admission, the patient regained sufficient 
respiratory function to be taken off invasive ventilation. The sedation was weaned without 
clinical deterioration and a week later, the patient spontaneously opened her eyes. Treatment 
was resumed with IvIg and cyclophosphamide at a reduced dose, due to lymphopenia. Over 
the next months, further neurological improvement occurred, but she also developed a 
fluctuating very aggressive and violent behavioral disorder, which is well described during the 
recovery phase of NMDAe, to the point where she became almost unmanageable in somatic 
care. The patient was discharged to a rehabilitation clinic after 313 days of hospitalization. 
Since then she has continuously improved and now lives at home, independent in her 
activities of daily living and takes no medication besides receiving rituximab every 6 months 
to reduce the risk of a relapse. During the next two years, MRI showed a substantial recovery 
in brain volume (Fig. 2). Additional analyses of tissue injury biomarkers on stored CSF 
revealed high levels of neurogranin, a postsynaptic protein enriched in dendritic spines and a 
marker of synaptic pathology (Portelius E et al, 2015), that subsequently were normalized 
(Fig 1). Levels of tau, phopho-tau (pTau) and soluble amyloid precursor protein alpha 
(sAPPa) and beta (sAPPb) were also moderately elevated early on (data not shown). In 
contrast, the glial markers glial fibrillary acidic protein, S100B and YKL-40 were low 
throughout the disease course. 
 
3. Discussion 
Refractory NMDAe constitutes a great clinical challenge, since it is often associated with 
prolonged intensive care and a high rate of mortality (Titulaer et al., 2013). To the best of our 
knowledge, the case presented here had the longest uninterrupted ICU period so far published 
with a relatively beneficial outcome. Despite treatment with immune suppressants such as 
rituximab and cyclophosphamide, the condition did not improve. Furthermore, the nerve 
injury marker NFL remained at a moderate to high level and the patient was not improving. 
Therefore, additional treatment with tocilizumab and bortezomib was given, which led to a 
clear clinical improvement. It is impossible to attribute the improvement to any single 
immune suppressant, but it likely represents a combination of several treatments. However, it 
is clear that the combination of rituximab, administered both in the periphery and directly into 
the intrathecal compartment, targeting CD20 expressing B cells, and bortezomib that targets 
plasma cells, on theoretical grounds should provide a strong brake on humoral immunity. 
Still, autoreactive NMDA receptor antibodies remained high in our patient despite clinical 
improvement. This is in line with new studies indicating an effect of bortezomib in refractory 
anti-NMDAe.(Behrendt et al., 2016; Scheibe et al., 2017) Almost two years after disease 
onset, levels of autoantibodies are relatively high, suggesting that autoantibody levels detected 
by standard clinical measures are not fully reliable for guiding treatment decisions. To our 
knowledge is this is the first time NFL levels have been monitored throughout the disease 
course. Despite early and aggressive treatment, levels of NFL continued to rise and peaked at 
four months after admission, three months after the initial surge of anti-NMDAR antibodies. 
The fact that NFL reflects neuroaxonal degeneration, the most important determinant of 
permanent neurological disability in inflammatory conditions such as multiple sclerosis, 
supports its use also in conditions such as NMDAe (Comabella and Montalban, 2014). Still 
the levels of NFL recorded here were relatively low given the severity of the condition and in 
relation to what is observed in for example severe traumatic brain injury (Al Nimer et al., 
2015). In contrast to the delayed peak of NFL, especially neurogranin, but also tau, pTau, 
sAPPa and sAPPb, peaked early in the disease course. Taken together, this suggests that 
NMDAe initially leads to predominantely synaptic/dendritic degeneration with subsequent 
secondary nerve cell or long tract neuroaxonal injury, which could explain the relatively good 
prognosis in spite of the development of pronounced brain atrophy. The mainly fronto-
temporal atrophy in this case also fits with the distribution pattern of NMDA receptors 
(Dalmau J et al., 2008). Nevertheless, due to the severity of neurological deficits and 
substantial mortality seen in severe NMDAe, aggressive immune suppression targeting 
different aspects of humoral immunity is warranted. 
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Fig. 1. Temporal profiles of cerebrospinal fluid neurofilament-light (NFL; pg/mL) and neurogranin 
(NG; pg/mL) levels (left X axis, filled and open circles, respectively), as well as anti-NMDA receptor 
cerebrospinal fluid (filled squares) and serum (open squares) antibody titres, respectively (right X 
axis). The patient needed invasive ventilation due to intractable epileptic seizures early in the disease 
course in spite of aggressive anti-epileptic and immune modulating drug treatment. The sequential 
timing of subsequent immune modulation is indicated in the figure. Btz=bortezomib; 
Cy=cyclophosphamide; IvIg=intravenous immunoglobulin infusion; MP=methylprednisolone; 
Ooph=bilateral oophorectomy; PLEX=plasmapheresis; RTX=rituximab; RTXi.t.= intrathecal 
rituximab;; TCZ=tocilizumab. 
 
Fig. 2. T1-weighted MRI images in the upper row (A-D) show the longitudinal decline of the mid-
sagittal corpus callosum area from baseline (A), after 2 months (B) and 4 months (C).  Partial recovery 
of the corpus callosum area can be seen after convalescence, 2 years after onset (D). Corresponding 
axial FLAIR images in the bottom row (E-H) illustrate an overall increase of the ventricle size and 
width of sulci as well as increasing size of focal white matter. 
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